Definition: Xerosis manifests as dry, scaly, itchy skin, particularly of the limbs and skin areas that were affected by acneiform eruption.1 Xerosis may develop into chronic Asteatotic eczema.1
Dry skin can be attributed to abnormal Keratinocyte differentiation leading to a disturbed stratum corneum and interference of Sebaceous gland function that translates into a loss of the water-retaining function of the epidermis.2,3
Onset: Some weeks to months after treatment initiation.9,10
Resolution: Complete resolution is usually seen within 4 weeks of completion of EGFRI treatment.
• L85.3 Xerosis cutis, dry skin dermatitis.
Dry skin covering <10% BSA and no associated Erythema or Pruritus.
Typical clinical presentations of grade 1 Xerosis can be viewed at the bottom of the page.
Covering 10-30% BSA and associated with Erythema or Pruritus; limiting instrumental ADL (refers to preparing meals, shopping for groceries or clothes, using the telephone, managing money etc).
Typical clinical presentations of grade 2 Xerosis can be viewed at the bottom of the page.
Covering >30% BSA and associated with Pruritus; limiting self care ADL (refers to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not confined to bed).
Typical clinical presentations of grade 3 Xerosis can be viewed at the bottom of the page.
1Segaert S & Van Cutsem E. Ann Oncol 2005; 16: 1425-1433.
2Lacouture ME. Nat Rev Cancer 2006; 6: 803-812.
3Candi E et al. Nat Rev Mol Cell Biol 2005; 6: 328-340.
4European Medicine Agency. Tarceva® (erlotinib) Summary of Product Characteristics 2009.
5European Medicine Agency. Iressa® (gefitinib) Summary of Product Characteristics 2009.
6European Medicine Agency. Erbitux® (cetuximab) Summary of Product Characteristics 2009.
7European Medicine Agency. Vectibix® (panitumumab) Summary of Product Characteristics 2009.
8European Medicine Agency. Tyverb® (lapatinib) Summary of Product Characteristics 2010.
9Osio A et al. Br J Dermatol 2009; 161: 515-521.
10Roé E et al. J Am Acad Dermatol 2006; 55: 429-437.